Fulcrum Therapeutics (FULC) 10% Owner Kevin Tang Buys Stock

What Happened Kevin Tang, a >10% owner of Fulcrum Therapeutics (FULC), purchased a total of 167,616 shares in open-market transactions on July 16–17, 2026. The filings report weighted-average prices of $3.56 (116,671 shares, $415,349) and $3.52 (50,945 shares, $179,326), for a combined outlay of about $594,675. These were purchases (transaction code P), which are generally taken as acquisition activity rather than dispositions.

Key Details

• Transaction dates and prices: Jul 16, 2026 — 116,671 shares @ $3.56 (weighted avg; individual trades ranged $3.50–$3.60); Jul 17, 2026 — 50,945 shares @ $3.52 (weighted avg; underlying trades ranged $3.46–$3.55).
• Total purchased: 167,616 shares for ~$594,675.
• Beneficial ownership: Per filing footnote, Tang-related entities (TCP, TCPI, TCP III, TCP IV) beneficially own 7,080,945 shares in aggregate; Mr. Tang has a pecuniary interest in those holdings.
• Filing timeliness: Form 4 was filed on Jul 20, 2026; the report covers transactions on Jul 16–17 and was filed within the normal SEC Form 4 timing requirements.
• Footnote disclosure: The reported prices are weighted averages; the Reporting Persons can provide breakdown of shares purchased at each price within the disclosed ranges upon request.

Context

• These were straightforward open-market purchases by a large/10% owner (institutional/affiliate interest through Tang-managed entities), not option exercises, gifts, or tax-withholding events. Purchases by insiders can be more informative than sales, but the filing does not state any motivation.